Cancer-reactive memory T cells from bone marrow: Spontaneous induction and therapeutic potential (Review)

Abstract

Cognate interactions between naïve tumor antigen (TA)-specific T cells and TA-presenting dendritic cells (DCs) are facilitated by secondary lymphoid organs such as lymph nodes or the spleen. These can result either in TA-specific tolerance or, depending on environmental costimulatory signals, in TA-specific immune responses. In the present review, we describe such events for the bone marrow (BM) when blood-borne TA, released from the primary tumor or expressed by blood circulating tumor cells or DCs enters the BM stroma and parenchyma. We argue that cognate T-DC interactions in the BM result in immune responses and generation of memory T cells (MTCs) rather than tolerance because T cells in the BM show an increased level of pre-activation. The review starts with the spontaneous induction of cancer-reactive MTCs in the BM and the involvement of such MTCs in the control of tumor dormancy. The main part deals with the therapeutic potency of BM MTCs. This is a new area of research in which the authors research group has performed pioneering studies which are summarized. These include studies in animal tumor models, studies with human cells in tumor xenotransplant models and clinical studies. Based on observations of an enormous expansion capacity, longevity and therapeutic capacity of BM MTCs, a hypothesis is presented which suggests the involvement of stem-like MTCs.

The NAD-dependent deacetylase SIRT2 regulates T cell differentiation involved in tumor immune response

“…In addition, HER2-enrich and basal-like carcinomas are characterized by highest CD8 tumor infiltrating lymphocytes and highest frequencies of memory T cells 25 , 26 . Researches in both human and mouse models have indicated that CD8 + T EM cells are enriched in the bone marrow of breast cancer patients/animals, but deficient in malignant effusions 27 - 29 . During the development of breast cancer, the human immune system is activated, and both CD4 + and CD8 + T E cells are mobilized to fight tumor cells ( Fig.…”

Immune Function and Diversity of Osteoclasts in Normal and Pathological Conditions

“…In regard of the huge number of publications dealing with DCs in secondary organs or even in tissues, very few are focused on mature BM DCs. As in other tissues, DCs represent a small population of BM cells (1–2%) expressing high levels of CD103 (118, 119). They are mainly located in the perivascular region where they form clusters, interact with T cells and provide survival signals to B cells (119).…”

Fifty Years of Clinical Application of Newcastle Disease Virus: Time to Celebrate!

“…This appeared sufficient to obtain peak anti-tumor DTH reactivity. This means three rounds of expansion and retraction of tumor-reactive T cells involving three waves of memory T cells changing between a status of activated effector memory (EMT) T cells in peripheral tissues and of resting central memory (CMT) T cells in the bone marrow [29]. …”